VIGENE BIOSCIENCES

Vigene develops gene delivery technologies with the mission to advance biomedical research and to make gene therapy affordable. It offers both research-grade and cGMP-grade AAV, lentivirus, and adenovirus-based products and custom services. Some of its product offerings include ready-to-ship genome-wide human cDNA ORFs on adenoviral or lentiviral vectors, AAV shRNA constructs, pre-made control GFP viruses, AAV biosensors developed in partnership with Janelia Research Campus, AAV alpha-synuclein vectors developed in partnership with The Michael J Fox Foundation, and many others. Vigene was founded in 2012 by senior scientists with expertise in the fields of virology and gene therapy. It is headquartered at Rockville, Maryland.